AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.


Read more

Targeted therapeutical areas

Read more

AlzProtect starts a new clinical study on the absorption of AZP2006 according to food intake

September, 19 2018 Read more

AlzProtect, planning its entry into phase 2, appoints Noëlle CALLIZOT as director of...

March, 26 2018 Read more